MGRM Monogram Technologies Inc

Monogram Spearheads Effort to Improve Disease Management for All HIV Patients and Physicians SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (NASDAQ:MGRM) announced today that Medi-Cal has expanded its coverage of HIV resistance testing to include treatment naive patients as well as patients failing therapy. While genotypic resistance testing has traditionally been covered for patients who fail anti-HIV treatment, the expanded coverage allows for baseline genotypic resistance testing for all HIV infected patients, including those who are newly diagnosed and who are treatment naive. Medi-Cal is California's Medicaid program, which provides medical service coverage for low-income and disabled individuals. This coverage expansion was driven by scientific evidence that documents an increasing prevalence of patients who become infected with drug resistant virus: up to 16% in some geographic areas. Drug resistant virus may persist during the pre-treatment phase of HIV infection. The BGRT identifies anti-HIV drugs likely to be ineffective, when treatment becomes necessary, even when begun months or years later. Evidence shows BGRT guided initial therapy results in longer time of viral suppression. The evidence was compiled by physician experts whose efforts were supported by Monogram Biosciences and advocates working to better the lives of patients living with HIV. Guideline recommendations from a antiretroviral guidelines Panel convened by the Department of Health and Human Services, Office of AIDS Research Advisory Council and the Henry J. Kaiser Family Foundation documents scientific evidence that supports expanding BGRT coverage to include chronically infected HIV treatment na�ve patients. Specifically, the Panel recommended performing BGRT prior to initiating antiretroviral therapy in patients with acute or chronic HIV infection. "We applaud Medi-Cal for setting coverage policies designed to bring personalized care to patients infected with HIV." says Tien Bui, Monogram Vice President of Medical Affairs. "Medi-Cal's coverage expansion is an important step towards ensuring that HIV patients and their physicians across California can make the best, most informed treatment decisions possible." For more information on the New Policy and Frequency Restrictions for HIV Drug Resistance Testing please visit the following section of the Medi-Cal website: http://files.medi-cal.ca.gov/pubsdoco/publications/bulletins/ob/obbull_e.asp About Monogram Biosciences, Inc. Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com/. Forward Looking Statements Certain statements in this press release are forward-looking. These forward-looking statements include references to the potential for an HIV drug that requires a molecular diagnostic for patient selection. These forward- looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that regulatory authorities may not require a molecular diagnostic for patient selection for an HIV drug, risks related to the implementation of the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors or entry inhibitors; the use of our Co-Receptor Tropism Assay for patient use in the event of approval of any CCR5 inhibitors; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payors will authorize reimbursement for our products and services; whether the FDA or any other agency will decide to further regulate our products or services; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause our actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. Trofile is a trademark of Monogram Biosciences, Inc. Contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare Tel: 650 624-4576 Tel: 415 677-2700 DATASOURCE: Monogram Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief Financial Officer of Monogram Biosciences, Inc., +1-650-624-4576, ; or Jeremiah Hall of Feinstein Kean Healthcare, +1-415-677-2700, Web site: http://www.monogrambio.com/

Copyright